| 4 | Venrock Adviser, LLC | 3.6M | $93.7M | 0.0% | 22.019% | 2.84% |
| 5 | BlackRock, Inc. | 3.2M | $82.2M | +1321.6% | 19.321% | 0.00% |
| 6 | FCPM III SERVICES B.V. | 2.4M | $63.5M | 0.0% | 14.915% | 8.46% |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 2.4M | $62.4M | +0.0% | 14.663% | 0.54% |
| 8 | VIKING GLOBAL INVESTORS LP | 2.3M | $60.1M | 0.0% | 14.121% | 0.17% |
| 9 | Jupiter Topco LLC | 2.3M | $59.3M | — | 13.948% | 0.02% |
| 10 | Remedium Capital Partners, LLC | 2.0M | $53.2M | 0.0% | 12.498% | 11.78% |
| 11 | Commodore Capital LP | 1.9M | $50.4M | 0.0% | 11.848% | 3.00% |
| 12 | JPMORGAN CHASE & CO | 2.1M | $49.8M | — | 12.581% | 0.00% |
| 13 | BRAIDWELL LP | 1.6M | $42.1M | +81.1% | 9.901% | 1.56% |
| 14 | Bellevue Group AG | 1.6M | $42.1M | -29.5% | 9.892% | 0.89% |
| 15 | STATE STREET CORP | 1.5M | $40.2M | +740.3% | 9.443% | 0.00% |
| 16 | a16z Capital Management, L.L.C. | 1.2M | $32.2M | 0.0% | 7.553% | 0.23% |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 1.2M | $32.0M | -15.1% | 7.510% | 0.04% |
| 18 | PERCEPTIVE ADVISORS LLC | 1.2M | $31.8M | 0.0% | 7.473% | 0.48% |
| 19 | WELLINGTON MANAGEMENT GROUP LLP | 1.1M | $27.5M | 0.0% | 6.465% | 0.00% |
| 20 | Blackstone Inc. | 1.0M | $26.1M | +99.2% | 6.128% | 0.07% |
| 21 | Cormorant Asset Management, LP | 1.0M | $26.0M | -34.4% | 6.110% | 1.33% |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 965K | $25.1M | +300.4% | 5.899% | 0.00% |
| 23 | Siren, L.L.C. | 900K | $23.4M | 0.0% | 5.499% | 0.47% |
| 24 | UBS Group AG | 840K | $21.9M | +423.8% | 5.134% | 0.00% |
| 25 | Vestal Point Capital, LP | 575K | $15.0M | -4.2% | 3.513% | 0.35% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DMRA — a direct measure of their conviction.
| 8.93% |
| +0.04 pp |
| $0M |
| 33% |
| Q4 2024 | 11 | +10% | 8.89% | +0.84 pp | $1M | 58% |
| Q3 2024 | 10 | — | 8.05% | — | $2M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
DMRA institutional ownership rose by 0.00 percentage points quarter-over-quarter, with a net change of +34 holders.
The top 10 institutions account for 62.2% of all reported 13F value in DMRA, and the top 25 account for 91.3%.
Across the largest Oncology Biotech peers, institutional ownership levels are: FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%), NXTS (3.3%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.